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ABSTRACT  
Loco-regional recurrence of breast cancer poses significant clinical problems due to frequent 
inoperability once the chest wall is involved. Early detection of recurrence by molecular imaging 
agents against therapeutically targetable receptors, such as c-Met, would be of potential benefit. The 
aim of this study was to assess [18F]AH113804,a peptide-based molecular imaging agent with high 
affinity for human c-Met, for the detection of early-stage loco-regional recurrence in a human basal-
like breast cancer model, HCC1954. Methods: HCC1954 tumor-bearing xenograft models were 
established, and [18F]AH113804 was administered. Distribution of radioactivity was determined via 
positron emission tomography (PET) at 60 min post radiotracer injection. PET and CT (computerized 
tomography) images were acquired 10 days after tumor inoculation, to establish baseline distribution 
and uptake, and then on selected days after surgical tumor resection. CT images and caliper were 
used to determine the tumor volume. Radiotracer uptake was assessed by [18F]AH113804 PET 
imaging. c-Met expression was assessed by immunofluorescence imaging of tumor samples and 
correlated with [18F]AH113804 PET imaging results. Results: Baseline uptake of [18F]AH113804, 
determined in tumor-bearing animals after 10 days, was approximately 2-fold higher in the tumor as 
compared to muscle tissue or the contralateral mammary fat pad. The tumor growth rate, determined 
from CT images, was comparable between the animals with recurrent tumors, with detection of tumors 
of low volume (<10 mm3) only possible by Day 20 post tumor resection. [18F]AH113804 PET detected 
local tumor recurrence as early as six days after surgery in the recurrent tumor-bearing animals, and 
exhibited significantly higher [18F]AH113804 uptake (in comparison to mammary fatty tissue) with a 
target to background (muscle) ratio of approximately 3:1 (p<0.01). The c-Met expression of individual 
resected tumor samples, determined by immunofluorescence, correlated with the respective 
[18F]AH113804 imaging signals (r=0.82; p<0.05). Conclusion: [18F]AH113804 PET provides a new 
diagnostic tool for the detection of c-Met-expressing primary tumor and has potential utility for the 
detection of loco-regional recurrence from an early stage. 
 
Keywords 
PET/CT imaging, basal-like breast cancer, HCC1954, c-Met, AH113804, cancer, loco-regional 
recurrence   
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INTRODUCTION 
The proto-oncogene c-Met is a receptor tyrosine kinase activated by the ligand hepatocyte growth 
factor (HGF). The HGF/c-Met signaling axis has been described as a promoter of cancer cell growth, 
angiogenesis, invasion and metastasis (1). Overexpression of c-Met is associated with poor prognosis 
and a more malignant tumor phenotype (2,3). Several c-Met inhibitors are currently under evaluation 
in clinical trials, either as stand-alone therapies or in concomitant treatment (4). c-Met is 
overexpressed in various solid tumors (5), including breast cancer (BC), with higher expression in 
Basal-like Breast Cancer (BLBC) than in other intrinsic cancer subtypes (6) . BLBC, which accounts 
for up to 15% of all BCs, exhibits a high rate of loco-regional recurrence after initial therapy (7-10). 
Although treatment of localized disease has improved over the past decades, up to 45% of 
BC patients suffer a local, regional or systemic relapse within 8 years after initial therapy (8). While 
systemic relapse in the form of distant metastasis is still regarded as incurable according to current 
treatment guidelines, loco-regional recurrence of BC should be treated with curative intention (11). 
Treatment success crucially depends on the earliest possible diagnosis, before chest wall involvement 
or further organ invasion prevents any form of aggressive treatment (12). Established guidelines for 
post-therapy monitoring in BLBC feature mammography and clinical examination which frequently fail 
to identify local tumor relapse at a sufficiently early stage (13). 
Magnetic resonance imaging (MRI) and FDG-PET/CT offer a comparably higher sensitivity 
and specificity for detection and characterization of BC relapse (14). However, differentiation of 
recurrent BC from inflammatory or infectious processes, and the identification of small lesions (tumor 
size <20 mm) still impose challenges for FDG-PET (15,16). c-Met targeted imaging could provide 
such a tool to further improve the performance of post-treatment surveillance, and could aid patient 
stratification for targeted therapy. 
For this study we chose the novel, peptide-based molecular imaging agent [18F]AH113804 
(Fig 1A) which binds to human c-Met with high affinity (Kd≈2 nM), has a favorable kinetic profile, 
exhibits specific uptake in c-Met positive tumor tissue and rapid systemic clearance (17). This enables 
for diagnostic PET imaging as early as one hour after administration (17). The safety, 
pharmacokinetics and imaging characteristics have all been assessed using GE-137, the fluorescent-
labelled analogue of AH113804, in healthy volunteers and in patients at high risk of colorectal 
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neoplasia (17).These initial studies in humans suggested that GE-137 was safe, and that it may 
improve visualization of colonic polyps, which display a high level for c-Met (17). 
In this study, we assessed [18F]AH113804-driven PET for the early detection of loco-regional 
tumor recurrence in a preclinical model of BLBC. 
 
MATERIALS AND METHODS 
Cell culture 
Human basal-like subtype breast cancer cells HCC1954 (CRL-2338) were obtained from the 
American Type Culture Collection and cultured in RPMI 1640 (Invitrogen) with 10% fetal calf serum 
(Bodinco BV) and 2 mM L-glutamine (Invitrogen) at 37 °C in a fully humidified atmosphere containing 
5% CO2. 
 
Western blotting 
Immunoblotting was performed as described in ref (18). Detection of bound antibody was with 
horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence 
(ThermoScientifc Fisher) with G-Box, Syngene. 
 
Tumor xenograft model 
All animal studies were performed in compliance with the UK Home Office Animals (Scientific 
Procedures) Act 1986. Female SCID (Severely Immunodeficient) mice (17 to 19 g at time of first 
procedure, Charles River UK) were subcutaneously injected with 4×106 cells in 0.1 mL of a 1:1 
mixture of medium and Matrigel (BD Biosciences) in the second right mammary fat pad. Tumor size 
was measured twice per week by caliper. The volume for the tumor was estimated as length*width2/2. 
Further details on the tumor xenograft model are given in the Supplementary Methods.  
 
Radiosynthesis of [18F]AH113804 
Synthesis of the peptide is described in the supplementary section of ref (17). Details of the 
radiosynthesis of [18F]AH113804 are given in the Supplementary Methods. 
 
CT and PET imaging 
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Small-animal PET/CT imaging was performed using microPET P4 (Concorde) and microCAT 
II (ImTek Inc.) systems as described earlier (19). Each animal was injected intravenously (iv) with 
approximately 7 MBq (0.1 mL) [18F]AH113804. Further details of the imaging procedure are given in 
the Supplementary Methods.  
Tumor and contralateral mammary fat pad uptake are presented as target-to-muscle retention 
ratio (TMRR). Further details are given in the Supplementary Methods.  
 
Ex vivo tissue analyses 
Details of all ex vivo tissue analyses are given in the Supplementary Methods. These include 
histology of formalin-fixed, paraffin-embedded tumor and quadriceps muscle, and [18F]AH113804 
autoradiography and immunofluorescence staining of snap-frozen tumor tissue. 
 
Statistical analysis 
Unless otherwise stated, group averaged data are presented as mean ± standard error of the 
mean (SEM). The observed skewed distribution of TMRR measures was lessened by logarithmic 
transformation, see Supplementary Methods. All statistical analyses were performed in R version 
3.1.2 (R Project for Statistical Computing, Vienna, Austria). 
 
RESULTS 
Synthesis of [18F]AH113804 
Total synthesis time on the automated platform was 49 min. For all synthesis runs, the decay 
corrected end-of-synthesis yield was between 38 and 41%, with a radioactive concentration (RAC) 
between 600 and 800 MBq/mL. The radiochemical purity was always >90%, the chemical content 
between 15 and 20 µg/mL, and specific activity approximately 100 GBq/µmol for each test item. 
 
c-Met expression level in HCC1954  
Human c-Met protein expression level was assessed in HCC1954, compared to HT-29 (high 
c-Met expressing) and U87 (moderate c-Met expressing) cell line lysates. The data shows 
upregulation of c-Met in the HCC1954 cell line (Suppl Fig 1). Burggraff et al. assessed the specificity 
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of GE-137, performing a competition study in HT-29 tumor bearing mice which showed a reduction in 
tumor uptake of GE-137 when co-administrated with an excess of unlabeled peptide (17). 
 
Tumor targeting of [18F]AH113804 
Baseline uptake of [18F]AH113804 (Fig 1A) was assessed in 8 tumor-bearing animals using 
PET imaging at 10 days post tumor inoculation (Fig. 1B). Levels of radioactivity at 60 minutes pi were 
4.9±0.6% ID/mL in kidney, 2.9±0.3% ID/mL in liver, and 2.0±0.2% ID/mL in blood. PET imaging 
(Fig 1C) revealed a significant difference between the uptake of [18F]AH113804 at the tumor site 
(1.5±0.2% ID/mL, white arrowhead) compared to both contralateral mammary fat pad (0.8±0.1% 
ID/mL, blue arrowhead) and muscle (0.8±0.1% ID/mL) at 60 minutes p.i. Ex vivo biodistribution 
studies, following PET imaging on Day 50 post tumor resection, confirmed [18F]AH113804 
accumulation in tumor was significantly higher compared to muscle (2.5±0.6% ID/g vs. 0.9±0.2%ID/g 
at 70 min pi, n=3. p<0.05. Suppl Fig 2). 
 
Early-stage recurrent tumor growth is first detected with [18F]AH113804, later by CT, and last 
by palpation 
Following tumor resection 14 to 16 days after inoculation, 5 animals were found to exhibit 
recurrent tumor growth, confirmed by necropsy after final imaging. The remaining 3 animals did not 
exhibit any tumor re-growth (by caliper measurements).  However, there was lack of correlation 
between tumor size by caliper and uptake of the tracer at the tumor site (Suppl Fig. 3). Tissue from 
the site of injection for one of the non-recurrent mice was stained. Negativity for tumor cells and 
human c-Met expression by IHC was confirmed (Suppl Fig. 4). In this case, the %ID/g in the ROI was 
0.6 (c.f. the %ID/g at the contralateral site was 0.5).  
Analysis of [18F]AH113804 PET images provided evidence for the presence of loco-regional 
recurrence from Day 6 post-resection in these 5 animals (Figure 2A). There was some degree of 
variation in the uptake of radioactivity at the tumor site in individual animals on each study day (Suppl 
Table 1). However, overall uptake on each day was comparable to that observed in the tumors pre-
resection. The TMRR was significantly higher at the tumor resection site in comparison to the 
contralateral mammary fat pad on Day 6 (2.7±0.3 vs. 1.0±0.3, p<0.001; n=5; Fig 2B). Uptake of 
[18F]AH113804 at the site of resection remained clearly visible in the PET images on subsequent 
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days,  with the TMRR significantly smaller in the contralateral mammary fat pad on Day 13 (1.6±0.2 vs 
0.9±0.2, p<0.01), Day 20 (1.6±0.1 vs 0.9±0.2, p<0.001) and Day 36 (1.5±0.8 vs 0.9±0.2, p<0.01). At 
Day 50 post tumor resection, the TMRR was also higher for the tumor site (1.7±0.7) than for the 
contralateral mammary fat pad (1.0±0.0), although this difference was not statistically significant. No 
specific [18F]AH113804 retention was detected in the contralateral mammary fat pad with levels of 
radioactivity in this region comparable to muscle tissue for all time points (Suppl Fig 5). 
By Day 20 post tumor resection, the mean tumor volume determined by CT measurement 
was approximately 7.0±12.5 mm3 (Fig 3A&B). Palpable tumor recurrence was detected from Day 29 
post tumor resection (Fig 3A). 
 
[18F]AH113804 retention in tumor tissue versus systemic clearance 
Systemic clearance of [18F]AH113804 was studied in selected tumor-bearing mice over the 
first 60 min pi by dynamic PET imaging. Figure 4A shows the distribution of [18F]AH113804 at 15 min 
(13-18 min) and 60 min (55-65 min) p.i. A decrease in [18F]AH113804 signal is observed in the major 
perfused organs, and retention of [18F]AH113804 at the tumor site (Fig 4B). 
Figure 4C displays the change in TMRR from 5 min to 60 min pi in relation to TMRR at 5 min p.i. 
While the tumor TMRR continuously increased, TMRRs for lungs, liver, heart and others decreased. 
 
Autoradiography and immunohistochemical analysis confirm [18F]AH113804 accumulation in c-
Met positive tumor tissues 
A heterogeneous pattern of [18F]AH113804 distribution was observed within the tumor, with 
viable tissue in the tumor periphery exhibiting a positive signal while the central tumor regions 
exhibited only low activity (Figure 5A). H&E staining and immunohistochemistry of consecutive tumor 
slides  revealed a large number of c-Met positive tumor cells (Figure 5B, left and right panels 
respectively). Both recurrent and primary tumors showed necrotic areas in H&E devoid also of c-Met 
(IHC) and displaying low [18F]AH113804 uptake (Suppl. Fig 6&7). 
 
Ex vivo histology correlates with the PET images 
Following immunofluorescent staining (Figure 6A), c-Met expression levels were quantified 
across whole tumor slides (Figure 6B).A significant correlation was found between c-Met expression 
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and in vivo PET (r =0.82, p=0.023. n=7), suggesting [18F]AH113804 signal in tumor at 60 min pi to be 
representative of c-Met expression. A similar correlation was observed between c-Met expression 
determined by IHC and [18F]AH113804 signal in vivo (r=0.83, p=0.0015) (Suppl Fig 8). 
In addition, it was found that the variation in the c-Met expression levels observed across the 
tumor samples (displayed in Fig 6B) was due to the tumor size. Indeed, a correlation (r = 0.83; p = 
0.0005) was identified between the total c-Met intensity level and the surface area of the tumor 
sample (Suppl. Fig 9).  
 
DISCUSSION 
Early detection and identification of tumor relapse enables improved loco-regional recurrence 
control resulting in an increased quality of life and better overall survival for BC patients (20). Current 
surveillance guidelines have been shown to be less effective in the detection of loco-regional 
recurrence than the more expensive, yet more sensitive, approaches such as MRI or radionuclide 
imaging (Single-photon emission computed tomography, PET) (13,14). It is believed that either 
individually, or as a companion test for established diagnostic approaches, targeted molecular 
imaging of specific tumor markers bears the potential to positively change BC follow-up; especially in 
patients presenting with a high risk of relapse such as BLBC patients (20,21). 
 
[18F]AH113804 is known to have a high affinity for human c-Met, as demonstrated in studies 
by Evans et al., where the in vivo affinity of [18F]AH113804 was determined via receptor blocking in 
HT-29 xenograft tumour mouse models (22) . [18F]AH113804 clears fast from plasma and non-target 
tissues (such as liver, lungs and heart), allowing for high contrast imaging after injection, and 
improving the sensitivity for tumor detection, as confirmed by PET imaging in this study. 
 
Our study shows that [18F]AH113804-driven PET imaging allowed for early detection of loco-
regional tumor recurrence in HCC1954 tumor-bearing mice after surgery. [18F]AH113804 uptake and 
retention in the lungs and heart, reflecting the non-specific blood pool distribution of [18F]AH113804 
decreased constantly over the observation period. In contrast, a constant signal was observed within 
the region of tumor regrowth, indicative of specific accumulation of [18F]AH113804 due to target 
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binding. [18F]AH113804 allows for excellent tissue penetration, and the in vivo PET imaging revealed 
satisfactory tumor to non-target (muscle) tissue ratio from one hour p.i. 
 
We were able to detect statistically significant differences in tumor uptake compared to 
contralateral mammary fat pad at Days 6, 13, 20 and 36 after tumor resection. The lack of statistical 
significance at the latter timepoints is most likely due to the lower, inhomogenous distribution of 
radioactivity in the tumors. PET images from some of those recurrent tumor bearing animals (images 
not shown) showed evidence of peripheral uptake only, indicative of necrosis in the tumor core. 
 
Currently [18F]FDG is used in PET diagnostics for detection and staging in cancer. Numerous 
studies have revealed that other, more target-specific tracers would be beneficial for the detection of 
loco-regional recurrence (23). In a study of patients with breast cancer, it was shown that tumour size 
was an important factor when correctly diagnosing patients (24). A review of 111 patients showed that 
a tumor size of less than 10 mm was a significant predictor of a false negative [18F]FDG PET result 
(16). In our study, a specific signal from [18F]AH113804 could be detected, even when the recurrent 
tumor was not yet observable via CT. A previous study by Cullinane et al. found [18F]FLT to be 
superior over [18F]FDG in assessing the effect of the c-Met inhibitor crizotinib in human glioblastoma 
and human gastric cancer pre-clinical models (25). When tumor size decreased within 1 week of 
treatment, [18F]FDG uptake remained unchanged while [18F]FLT PET showed a marked decrease in 
uptake. [18F]FLT is reflective of cell proliferation, and as such was indicative of tumor therapy 
response. Still the use of [18F]FLT as a marker for proliferation has been heavily debated, with reports 
suggesting that results should be viewed with caution (26).  Such studies denote the importance of 
targeting radiotracers  such as [18F]AH113804 for accurate tumor detection and patient monitoring. 
 
Our study demonstrates correlation between c-Met from the tumor samples and the maximum 
uptake (% ID/mL) from [18F]AH113804 at those sites in the corresponding PET images. A recent study 
using an optical analogue of AH113804 (GE-137) also showed a good concordance between the 
expression of c-Met and the optical signal detected (17,27). 
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Other groups have investigated the use of both monoclonal antibodies and anticalins as 
probes for c-Met imaging. 89Zr-db-/76Br-ornartuzumab and 89Zr-PRS-110 were developed and 
assessed for visualization of c-Met positive tumors in preclinical models (28,29). Optimal imaging time 
points were identified to be between 2 and 5 days after tracer administration, thus hampering potential 
routine clinical use as diagnostic agents. In contrast, the biodistribution of [18F]AH113804 permitted 
early imaging after tracer administration. Similarly, Li et al. explored the use of c-Met targeting scFv-
cys dimers in Non-Small Cell Lung Cancer xenografts. Despite showing very high affinity for c-Met, 
good contrast immunoPET imaging was achieved only at 20 hours after injection (30). 
 
The ubiquity of c-Met dysregulation in malignant disease and its known influence on tumor 
progression make c-Met an attractive target for diagnostic targeting and therapeutic intervention in 
multiple cancer types. Phase II and III clinical studies, evaluating c-Met inhibition in gastroesophageal 
cancer, lung cancer and hepatocellular carcinoma have shown encouraging results with clear benefit 
for the individual patient (4,31,32). 
 
It is hypothesized for BC, as well as for those cancer types that react more favourably to c-
Met inhibition, that stratification of patients according to aberration in the c-Met axis resulting in target 
overexpression would strongly increase the efficiency of targeted treatment. 
[18F]AH113804 mediated PET signals proved to reflect the c-Met expression in individual tumors in 
our BC model, suggesting that this tracer could also serve as such a companion diagnostic for patient 
selection and for therapeutic purposes. Future studies to evaluate this utility are required. 
 
 
CONCLUSION 
This study demonstrates that [18F]AH113804 PET provides a new diagnostic tool for the 
detection of c-Met-expressing primary tumor and has potential utility for the detection of loco-regional 
recurrence from an early stage. Further preclinical work is warranted to determine whether 
[18F]AH113804 uptake in the regrowth provides a useful predictive tool for anti-c-Met therapeutic 
intervention.  
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Figure 1. Biodistribution of [18F]AH113804 and HCC1954 tumor. (A) Molecular structure of 
[18F]AH113804. (B) Distribution of [18F]AH113804 in selected organs and tissues in HCC1954 tumor 
xenografts 10 days p.i. Statistically significant differences were observed in the uptake of 
[18F]AH113804 in tumor versus muscle and contralateral side (Students t-test, mean±SEM, n=8, *: 
p<0.05). (C) CT and PET/CT images of a representative tumor-bearing mouse 10 days p.i. 
demonstrates [18F]AH113804 signal at the tumor site (white arrow), but not at the contralateral site 
(blue arrow).  
14 
 
 
 
Figure 2. Early detection of tumor regrowth using [18F]AH113804 for PET imaging. (A) PET/CT 
images of a transverse section of a representative tumor-bearing mouse, 4 days before tumor 
resection and at selected days after resection, show [18F]AH113804 signal at the tumor site at 60 min 
p.i. For clarity, the PET signal only in the ROI is shown. (B) Target-to- muscle ratio in the tumor and 
contralateral sites. Statistically significant differences between both sites observed at Days 6, 13, 20 
and 36 (Students t-test, mean±SEM,  Day 4 pre-resection: n=8, Days 6 and 13 post resection: n=5, 
Days 20 and 36: n=4, Day 50: n=3. **p<0.01, ***p<0.001).  
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Figure 3. Detection of loco-regional tumor recurrence via CT and caliper measurements. (A) 
Growth curve of mean tumor volume obtained from caliper and CT measurements of the same group 
of animals, before and after primary tumor resection (mean±SEM, n=5 per study day, except days 20 
and 36: n=4, day 50: n=3). (B) Coronal CT slices of a representative tumor-bearing mouse before and 
after resection show the presence (white arrow) and regrowth of the tumor after resection. Tumor 
growth was observed by CT from day 20 onwards. 
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Figure 4. Biodistribution of [18F]AH113804 in a recurrent HCC1954 tumor-bearing mouse. (A-
left) Representative CT image of a HCC1954 xenograft mouse, acquired at Day 36 post resection. 
Recurrent tumor observed (White arrowhead). (A- middle and right) PET/CT at 15 min and 60 min 
p.i. of [18F]AH113804, with retained radioactivity in the tumor visible by 60 min p.i.. (B) Dynamic ROI 
analysis of PET/CT shows a constant concentration at the tumor site but steady decline in all other 
organs (n=1). (C) Data of panel B normalized to the first time point show the relative change with a 
clear increase for tumor (n=1). 
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Figure 5. Autoradiography and immunohistochemistry demonstrate [18F]AH113804  retention in 
c-Met positive HCC1954 tumor tissue.  
(A) Autoradiography performed ex vivo on a resected tumor confirms retention of the [18F]AH113804 
radiotracer in tumor tissues. A heterogeneous distribution of tracer within the tumor section could be 
observed, not visible at the limited spatial resolution of PET imaging. (B) H&E staining (upper) and c-
Met immunostaining (lower) of paraffin-embedded tumor and control skeletal muscle tissue (left and 
right columns respectively). H&E staining reveals the large, mitotic and disorganized phenotype 
characteristic of tumor cells, while immunohistochemistry reveals membranous c-Met staining in these 
cells. Scale bars=100 µm. 
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Figure 6. Uptake of [18F]AH113804 correlate with the c-Met expression level in the 
corresponding resected tumor samples. (A) Immunofluorescent staining for c-Met in resected 
tumor samples (Day 14, n=7). Low, medium and high c-Met staining examples highlighted panel B. 
(B) A positive correlation is found between (a) the Max %ID/mL of tumor ROIs from in vivo PET 
images, and (b) the c-Met protein expression level from immunofluorescent staining in the same 
tumors after resection. Pearson’s correlation coefficient=0.82 (P<0.05, n=7). 
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SUPPLEMENTARY MATERIAL 
 
 
 
 
 
Suppl Fig 1. Western blot of c-Met expression. Highest expression level of c-Met is found in HT-29, 
less in HCC1954 and very little in U87 cell lysate. Tubulin was used as a loading control. 
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Suppl. Fig. 2 [18F]AH113804 activity (% ID/g) from ex vivo assay of dissected organs and tissue 
samples from HCC1954 tumor bearing mice. Organs were excised at 70 min p.i. on Day 50 post 
tumor resection. A single t-test was performed to compare uptake of [18F]AH113804 uptake in tumor 
and muscle. A statistically significant difference was observed (p<0.05, n=3). P value was calculated 
in R version 3.1.2.   
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Suppl. Fig 3. No correlation observed between tumor size by caliper measurement and the 
uptake of the tracer at the tumor site. This graph shows the mean tumour measurement of all 
tumour-bearing mice at 6 timepoints, with its matching mean uptake of the tracer (measurement taken 
at day 4 pre tumor resection, day 0, day 6, day 13, day 20, day 36 and day 50 post tumor resection).  
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Suppl. Fig. 4. Immunohistochemical staining of mammary fat pad from a mouse that did not 
have a recurrent tumor after resection. The left panel represents the H&E staining of the sample 
that shows a clear presence of adipose tissue and ducts. No tumor cells were detected. The right 
panel shows staining for c-Met. No significant c-Met staining was observed. Scalebar represents 200 
µm. 
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Suppl. Fig. 5. Progressive increase in uptake of [18F]AH113804 at the tumor site post tumor 
resection. PET and CT image of a same tumor bearing mouse acquired on Day 6, Day 20 and Day 
36 post resection showing uptake of [18F]AH113804 at 60 min p.i. The recurrent tumour is clearly 
visible on the right flank of the animal (white arrowhead). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
24 
 
               
 
 
 
Suppl Fig 6: H&E staining E (left) and immunohistochemical staining for human c-Met (middle 
and right) on a representative tumour sample that was collected at day 14 post tumour 
inoculation. The tumour sample displays an area at its core devoid of cells. It also displays tumour 
cells at the periphery with fairly strong human c-Met staining. Presence of necrosis and membranous 
c-Met staining on tumor cells is visible on the right panel. Scalebars represent 200 µm. 
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Suppl Fig 7. Immunohistochemical staining for c-Met on a representative recurrent tumor 
sample. Left panel shows the whole tumor sample while the right panel shows a magnified area of 
this tumor sample. The tumor sample displays a core of necrosis. The right panel shows membranous 
staining for c-Met around the tumor cells while the necrotic area shows no staining for c-Met. 
Scalebars represent 200 µm. 
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Supp Fig 8. Uptake of [18F]AH113804 in tumors correlates with the c-Met expression level in 
samples of the same HCC1954 tumors. IHC detection of c-Met expression in FFPE preparation of 
tumor samples. Statistical analysis gave a Pearson’s correlation coefficient of 0.85 (P= 0.0015, n = 
10). Pearson r and P values were calculated in R version 3.1.2.   
  
27 
 
0.
0
5.
0×
10
08
1.
0×
10
09
1.
5×
10
09
2.
0×
10
09
2.
5×
10
09
3.
0×
10
09
3.
5×
10
09
4.
0×
10
09
4.
5×
10
09
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5
20.0
22.5
25.0
27.5
30.0
32.5
P = 0.0008
r = 0.83
Total c-Met intensity
S
u
rf
a
c
e
 a
re
a
 o
f 
tu
m
o
r 
s
a
m
p
le
s
 (
m
m
3
)
 
Suppl Fig 9 : Correlation between the surface area of viable tumour cells and the total c-Met 
intensity. The surface area measured includes areas with tumour cells only while excluding areas 
without cells, necrotic areas, and stroma. Statistical analysis gave a Pearson’s correlation coefficient 
of 0.83 (P = 0.0008, n = 12). P and r values were calculated in R version 3.1.2.   
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Suppl Fig 10: ROIs drawn in tumor and contralateral mammary fat pad. A. Representative CT 
(left) and CT/PET image (right) of  HCC1954 tumour xenograft bearing mouse at day 36 post tumour 
resection. The ROI drawn at the tumour site (white arrow) was then replicated at the contralateral 
mammary fat pad (pink arrow) using the coronal and transverse section. B. ROI volumes for the 
tumour (t1) and the contralateral site (c1) are very similar. The ROI were drawn manually separately 
but attention was given to draw similar sized shape ROI for both sites and then checking that the 
volume of the respective ROI were very similar using the analysis section of the AMIDE software.  
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Suppl. Fig. 11. Identification of an outlier through the fitting of a regression line. Red dots fall 
between the upper and lower 1 percentile of all residuals while the grey dot is identified as an outlier. 
Statistical analysis performed in R version 3.1.2.   
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Day MEAN (± SEM) 
Lowest 
Individual Uptake 
Observed 
Highest 
Individual Uptake 
Observed 
n 
-4 1.4 (0.2) 1.0 2.5 8 
6 2.1 (0.1) 1.6 2.4 5 
13 1.5 (0.2) 0.9 2.2 5 
20 1.5 (0.3) 1.1 2.5 4 
36 1.9 (0.7) 1.0 4.1 4 
50 1.2 (0.3) 0.9 1.7 3 
 
Supplementary Table 1. Uptake of radioactivity (%ID/mL) in HCC1954 tumors following 
[18F]AH113804 administration, as determined by PET imaging. 
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PET Imaging timepoint Number of mice 
imaged 
Number of mice 
with recurrent 
tumors 
10 days post implantation 8 N/A 
6 days post resection 8 5 
13 days post resection 8 5 
20 days post resection 6 4 
36 days post resection 6 4 
50 days post resection 6 3 
 
Supplementary Table 2. Number of mice used in this study and imaged at different PET 
imaging timepoints. Inclusion of the number of mice with visible recurrent tumors after tumor 
surgery.   
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Supplementary Methods: 
 
 
Tumor xenograft model (continuation): 
Initial PET scans with [18F]AH113804 were acquired 10 days after tumor inoculation. Fourteen 
to sixteen days after tumor cell implantation, animals underwent surgery for tumor excision, and were 
subsequently allowed to recover under sufficient analgesia.  
The animals were anaesthetized using 2.5% isofluorane in medical oxygen during the 
surgery. Area of the tumor site was cleaned using povidone-iodine. A 1 cm incision was then made 
around the tumor. A cotton swab was used to expose the tumor from the mammary fat pad. The tumor 
was then removed gently and completely from the mammary fat pad using scissors.  In some cases, 
when the tumor was stuck to the skin, the skin was also removed to ensure that there would be no 
visible remnant of the tumor. Sham surgery was not performed on the contralateral mammary fat pad 
as the project license would not allow 2 surgeries to take place in one animal.  
  The animals were monitored for up to 50 days post tumor resection for local tumor recurrence, 
with PET imaging carried out on selected days post resection (Suppl. Table 2). 
For autoradiography studies, female nude mice were inoculated with HC1954 cells in the second right 
mammary fat pad, according to the methods described above. Tumors were allowed to develop for 25 
days before use. 
 
 
Radiosynthesis of [18F]AH113804 (continuation): 
[18F]AH113804 (chemical structure presented in Fig. 1A) was synthesized on a FASTlab 
automated synthesizer (GE Healthcare, Chalfont St Giles, UK) in a 2-step process. First, 
[18F]fluorobenzaldehyde was synthesized from [18F]fluoride and purified on a MCX+ (Mixed Cation 
Exchange, Waters) cartridge. Then, [18F]fluorobenzaldehyde was conjugated to the peptide precursor 
and [18F]AH113804 was purified and formulated.  
 
[18F]Fluoride was recovered from irradiated target water on a QMA cartridge (Waters) and 
then eluted using Kryptofix and KHCO3 into a cyclic olefin copolymer reaction vessel and dried under 
a flow of nitrogen at 120 °C. Subsequent reaction with trimethylammonium benzaldehyde triflate in 
DMSO resulted in [18F]fluorobenzaldehyde. 
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In the second step, the peptide precursor was dissolved in an aqueous solution of aniline 
hydrochloride and added to the purified [18F]fluorobenzaldehyde to give crude [18F]AH113804. 
Purification was done on a tC18 SPE (Solid Phase Extraction) cartridge with acetonitrile in PBS 
(21.4% v/v) followed by PBS to remove residual acetonitrile. [18F]AH113804 was eluted into PBS 
(34 mL) from the tC18 cartridge with ethanol (2.4 mL) followed by PBS (2.6 mL) to give the formulated 
product (total volume 39 mL, ca. 6% EtOH). 
 
CT and PET imaging: 
Anesthesia (approximately 2% isoflurane in oxygen) was induced shortly before and 
maintained throughout imaging. PET imaging at 55-65 min post injection (pi) of [18F]AH113804. A 
whole body CT scan followed (projection exposure time 400 ms, tube voltage 45 kVp). Animals were 
allowed to recover from anesthesia. Occasionally static PET imaging was replaced by a dynamic 
series at 5-65 min pi [18F]AH113804. 
PET data were attenuation and scatter corrected, then reconstructed by filtered back 
projection. Images were manually coregistered and analyzed by Regions of Interest (ROI) employing 
AMIDE (http://amide.sourceforge.net).  
Imaging was performed at baseline (10 days post tumor inoculation, i.e. 4 days pre-resection) 
and on Days 6, 13, 20, 36 and 50 post tumor resection. 
3D ellipsoid ROIs were placed on the tumor in CT images to estimate tumor volume (Suppl 
Fig 10). Additional ROIs were placed in skeletal muscle (left forelimb), liver, left and right kidney, and 
heart (blood pool). All ROI PET data were expressed as decay corrected radioactivity concentration 
normalized to the injected dose (% ID/mL). 
Biodistribution of [18F]AH113804 was obtained for the mice on the final imaging day (Day 50 
post resection). Following PET/CT imaging, animals were sacrificed (approx. 70 min p.i.). Organs and 
tissues of interest were excised, weighed and radioactivity measured using a custom-built twin-crystal 
gamma counter. Ex vivo [18F]AH113804 uptake is expressed as percentage radioactive dose per 
gram of tissue (% ID/g). 
 
Autoradiography: 
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Autoradiography was performed on tumors harvested from nude mice 25 days after tumor 
inoculation. Mice were sacrificed 40 min after injection of approximately 7 MBq [18F]AH113804 and 
corresponding PET imaging. Tumors were excised, snap frozen and cut into 8 μm thick sections. 
Sections were then imaged in a Micro Imager (Biospace Lab, Paris) which provides a spatial 
resolution of 25 µm for 18F. Image acquisition duration was 90 min. 
 
Histology: 
Hematoxylin and eosin staining and c-Met immunohistochemistry were performed on 
consecutive 3µm thick tissue sections, employing the monoclonal rabbit antibody D1C1 (Ventana; 
diluted 1:30) against total c-Met. Antigen retrieval was employed (Standard Cell Conditioning 1/ 
Ventana). DAB (3,3'-diaminobenzidine) served as chromogen. Slides were processed with an 
automated system Ventana (BenchMark ULTRA, Roche, Switzerland), scanned with a Hamamatsu 
Nanozoomer 2.0 HT (Hamamatsu Photonics, Hamamatsu, Japan) and initially analyzed with 
Hamamatsu NDP.view2 viewing software. Quantitative analysis of the c-Met expression level was 
made using HistoQuest 4.2 (Tissugnostic, Vienna, Austria) software.  IHC detection and quantification 
of c-Met expression in FFPE preparation of tumor samples are described in the section below. 
 
Immunohistochemistry Data Analysis: 
All the histological slides were digitalized at magnification x20 (0.46 µm/pixel) using 
Hamamatsu Nanozoomer 2.0 HT. Digital images in ndp format were submitted for quantitative image 
analysis using HistoQuest software. HistoQuest uses patented algorithms to detect the individual cells 
of interest and assesses intensity of antigens in the cell nucleus, membrane and cytoplasm. The 
program automatically detects tissue which is subjected to color separation module to differentiate 
between the blue and the brown shade. Nucleus detection algorithm on the hematoxylin shade was 
used to detect all cell nuclei and was defined as master channel. A ring mask around each nucleus 
was used to analyze the staining intensity of non-master chromogen (DAB) in given cellular location. 
The staining intensity is measured as mean intensity of all pixels of a cell and the range of values is 
from 0 to 255. 
c-Met staining intensity was analyzed within 1.7 mm²  regions of interest (ROI) that were 
visually identified over the tumor enriched region. Staining intensity was analyzed in ring masks 
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around each nucleus using an algorithm that identifies stained cytoplasmic and membranous areas. 
Raw data included minimum and maximum pixel value for every individual cell within the ROI. The 
average minimum and maximum pixel values were calculated for the whole region. The obtained data 
correlated with values acquired from PET scans. 
 
Immunofluorescence: 
Tissues were permeabilized and stained similar to the procedure outlined previously (18). A 
monoclonal rabbit c-Met antibody (1:100, D1C2, Cell signaling), followed by an incubation with a goat 
anti-rabbit Cy3 secondary antibody (1:500, Sigma), were used. Total fluorescence in each sample 
was measured and total c-Met-related intensity was corrected for differences between each animal 
using the same threshold. It was quantified using the software package TRI2 (Paul Barber, Oxford 
Institute for Radiation Oncology). 
 
Statistical Analysis: 
SEM was calculated to estimate the precision of the sample mean. Paired t-test of log-
transformed TMRR was conducted to evaluate the difference between tumor and contralateral 
mammary fat pad uptake (Fig 2B). The correlation between total c-Met intensity from frozen tumor 
samples and the corresponding max %ID/mL for the uptake of [18F]AH113804 at the tumor site (Fig 
6B) is visualized with a scatter plot and Pearson correlation coefficients were calculated. The analysis 
was restricted to observations which fell between the upper and lower 5 percentile of all residuals, 
assigning any observation beyond this range as an outlier. This resulted in exclusion of one 
observation and the remaining seven observations were used in the final analysis (Suppl. Fig. 11). A 
two-sided P-value <0.05 was used to determine significance. 
 
 
 
